Marian Nakada
Venture Investments JJDC at Johnson & Johnson
Cambridge, Massachusetts
Overview
Work Experience
Board Observer
2024 - Current
Arkuda Therapeutics is a pharmaceutical company.
Raised $108,000,000.00 from Cormorant Asset Management, Pivotal bioVenture Partners, Pfizer Venture Investments, Surveyor Capital, Eli Lilly, Mission BioCapital, Tekla Capital Management and Atlas Venture.
Vice President, Venture Investments JJDC
2013
Focuses on pharmaceutical venture investments on the East Coast, in support of Janssen R&D objectives. Works closely with Boston Innovation Center colleagues, Therapeutic Areas and cross-R&D Functional Areas.
Johnson & Johnson is a healthcare provider, expertise in innovative medicine and MedTech for every patient & for everyone.
Advisor
2019
Provide input to shape the themes, topics and speakers for the Convergence Forum
Convergence Forum is a biotechnology company.
Member
2021
Board Observer
2021
Iterative Health develops technology that can benefit patients anywhere, regardless of socioeconomic or geographic barriers.
Board Member
2020
Board Chair
2019 - 2020
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Raised $259,000,001.00 from Pfizer Venture Investments.
Board Member
2013
Navitor Pharma is a developer of novel medicines designed to target specific nutrient-sensing proteins to treat diseases.
Raised $98,168,747.00 from SR One, Sanofi Ventures, Remeditex Ventures, Atlas Venture, Polaris Partners, Brace Pharma and Johnson & Johnson Robotics and Digital Solutions.
Board Member
2016 - 2023
The NEVCA fosters a collaborative, inclusive, and prosperous innovation ecosystem on behalf of New England's VC industry. Operating across four pillars - Venture Community, Regional Brand, Workforce Development, and Public Policy - the association's initiatives impact the community at large: events connect founders, funders, and innovators; legislative advocacy promotes economic growth; programs bolster professional development across the venture landscape.
Board Member
2018 - 2023
Twentyeight-Seven Therapeutics is focused on the modulation of functional non-coding RNA (ncRNA) to treat cancer and other human diseases. By targeting ncRNA modulating proteins (RMPs), we can use small molecules to modulate expression levels of oncogenes and other proteins of significance in disease.
Redona Therapeutics specializes in the modulation of functional non-coding RNA to treat cancer and other human diseases.
Raised $66,779,837.00 from Astellas Venture Management.
Board Observer
2014 - 2021
Accelerator Life Science Partners offers a comprehensive arsenal of business, scientific, and financial resources.